<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Akt signalling pathway plays vital roles in controlling cellular responses to insulin as well as in proliferation and survival </plain></SENT>
<SENT sid="1" pm="."><plain>Inhibition of Akt signalling leads to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, whereas hyperactivation of Akt promotes <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigate how modest changes in the activity of the Akt signalling pathway, to an extent that might be achieved by drug treatment, would impact on <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Using insulin-resistant PDK1(K465E/K465E) PH domain knock-in mice, we found that introducing the PTEN(+/-) mutation to slightly stimulate Akt restored <z:mpath ids='MPATH_458'>normal</z:mpath> insulin sensitivity </plain></SENT>
<SENT sid="4" pm="."><plain>Introducing the PDK1(K465E/K465E) PH domain knock-in mutation into <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-prone PTEN(+/-) mice, lowered Akt activity only by about 50%, but led to a delay in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> of âˆ¼4 months in a broad range of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>This was also accompanied by slower growth of B cell follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, as monitored by magnetic resonance imaging </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings imply that signal transduction inhibitors that lead to a modest reduction in Akt activity would not only delay <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> possessing elevated <z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> 3-kinase pathway activity but would also reduce the growth rate of developed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
</text></document>